Takeda Unit Gets Warning Letter On Marketing Velcade
This article was originally published in PharmAsia News
Executive Summary
A Takeda Pharmaceutical unit received a warning notice from U.S. FDA, accusing it of misleading potential patients in its promotional material for its cancer drugVelcade (bortezomib). The letter was issued to Takeda's Millennium Pharmaceuticals, which was accused of overstating the drug's effectiveness while omitting mention of its approved uses and risks. A spokeswoman for the U.S.-based subsidiary said the firm intends to respond to the warning letter. (Click here for more